Clinical trial Recruiting at 2 sites Observational Ages 18 and up

ATLAS-1: Longitudinal assessment of treatments for depressed mood

Official title: ATLAS-1: Advanced Trial for Longitudinal Assessment in Salma 1

Run by Salma Health, Inc. · NCT07528014 · Data updated 2026-11-12

This project will try to use clinical data from adults with depressed mood who receive esketamine, conventional TMS, or SAINT to build tools that predict which treatment is most likely to help.

More Depressed Mood trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment5000 (estimated)
SponsorSalma Health, Inc.
Academic / other
Locations2 sites (La Jolla, California and 1 other locations)
StatusRecruiting
StartedMarch 25, 2026
Main results expectedMarch 2036
Study endsMarch 2037
Registry record updatedApril 14, 2026
Trial IDNCT07528014 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 or older presenting with depressed mood who are prescribed esketamine, conventional TMS, or SAINT and can provide informed consent are ideal candidates.

Probably not a fit

People who are not receiving those specific treatments, are under 18, or have conditions that prevent safe participation in the study assessments may not benefit from this project.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects multimodal clinical data from adults treated for depressed mood in routine care at two Salma Health clinics and may incorporate authorized retrospective data from existing databases. Participants will be those prescribed esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) as part of standard care, with data used to develop and validate predictive models of treatment response. The approach focuses on real-world clinical measurements rather than experimental interventions and emphasizes model training and validation across available datasets. Outcomes will include model performance metrics and the feasibility of integrating such tools to inform treatment selection.

Why it matters

Potential benefit: If successful, the models could help clinicians choose the most promising treatment sooner, reducing trial-and-error and speeding relief for patients.

How similar studies have gone: Prior research using predictive models for TMS and ketamine-like therapies has shown promise in controlled settings, but these approaches remain experimental and need validation in real-world clinical datasets.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults (≥18 years) of any gender identity presenting for care with a depressed mood.
* Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care.
* Able to provide informed consent and comply with all study requirements.

Exclusion Criteria:

* Any condition deemed by the investigator to preclude safe participation in study assessments.

Where it's running

  • Salma Health
    La Jolla, California, United States
    Recruiting
  • Salma Health
    Laguna Hills, California, United States
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.